NeuroVive Appoints CEO
This article was originally published in Scrip
NeuroVive Pharmaceutcial AB has named Erik Kinnman CEO, succeeding interim CEO Jan Nilsson, who will resume his position as chief operating officer for the company – effective March 14, 2016. Kinnman has held various roles in clinical development, business strategy, business development and investor relations in biopharmaceutical companies including AstraZeneca and Sobi and also has experience in the financial sector.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.